Skip to main content

Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Piper Jaffray Downgrades Acorda Therapeutics To Underweight, PT To $16
Joe Young  
 
February 18, 2011 7:48am   Comments
Share:

Piper Jaffray has downgraded Acorda Therapeutics (NASDAQ: ACOR) from Neutral to Underweight and has lowered the price target from $24 to $16.

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

 

Related Articles (ACOR)

View Comments and Join the Discussion!

Posted-In: Acorda Therapeutics Piper JaffrayDowngrades Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com